Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
12
10
2021
revised:
16
12
2021
accepted:
20
12
2021
pubmed:
27
3
2022
medline:
6
4
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, receive a molecular WHO-recommended rapid diagnostic test (eg, Xpert MTB/RIF [Xpert] assay). To inform updated WHO tuberculosis screening guidelines, we conducted a systematic review and individual participant data meta-analysis to assess the performance of W4SS and alternative screening tests to guide Xpert testing and compare the diagnostic accuracy of the WHO Xpert algorithm (ie, W4SS followed by Xpert) with Xpert for all HIV-positive inpatients. We searched MEDLINE, Embase, and Cochrane Library from Jan 1, 2011, to March 1, 2020, for studies of adult and adolescent HIV-positive inpatients enrolled regardless of tuberculosis signs and symptoms. The separate reference standards were culture and Xpert. Xpert was selected since it is most likely to be the confirmatory test used in practice. We assessed the proportion of inpatients eligible for Xpert testing using the WHO algorithm; assessed the accuracy of W4SS and alternative screening tests or strategies to guide diagnostic testing; and compared the accuracy of the WHO Xpert algorithm (W4SS followed by Xpert) with Xpert for all. We obtained pooled proportion estimates with a random-effects model, assessed diagnostic accuracy by fitting random-effects bivariate models, and assessed diagnostic yield descriptively. This systematic review has been registered on PROSPERO (CRD42020155895). Of 6162 potentially eligible publications, six were eligible and we obtained data for all of the six publications (n=3660 participants). The pooled proportion of inpatients eligible for an Xpert was 90% (95% CI 89-91; n=3658). Among screening tests to guide diagnostic testing, W4SS and C-reactive protein (≥5 mg/L) had highest sensitivities (≥96%) but low specificities (≤12%); cough (≥2 weeks), haemoglobin concentration (<8 g/dL), body-mass index (<18·5 kg/m The W4SS and other potential screening tests to guide Xpert testing have suboptimal accuracy in HIV-positive inpatients. On the basis of these findings, WHO now strongly recommends molecular rapid diagnostic testing in all medical HIV-positive inpatients in settings where tuberculosis prevalence is higher than 10%. World Health Organization.
Sections du résumé
BACKGROUND
Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, receive a molecular WHO-recommended rapid diagnostic test (eg, Xpert MTB/RIF [Xpert] assay). To inform updated WHO tuberculosis screening guidelines, we conducted a systematic review and individual participant data meta-analysis to assess the performance of W4SS and alternative screening tests to guide Xpert testing and compare the diagnostic accuracy of the WHO Xpert algorithm (ie, W4SS followed by Xpert) with Xpert for all HIV-positive inpatients.
METHODS
We searched MEDLINE, Embase, and Cochrane Library from Jan 1, 2011, to March 1, 2020, for studies of adult and adolescent HIV-positive inpatients enrolled regardless of tuberculosis signs and symptoms. The separate reference standards were culture and Xpert. Xpert was selected since it is most likely to be the confirmatory test used in practice. We assessed the proportion of inpatients eligible for Xpert testing using the WHO algorithm; assessed the accuracy of W4SS and alternative screening tests or strategies to guide diagnostic testing; and compared the accuracy of the WHO Xpert algorithm (W4SS followed by Xpert) with Xpert for all. We obtained pooled proportion estimates with a random-effects model, assessed diagnostic accuracy by fitting random-effects bivariate models, and assessed diagnostic yield descriptively. This systematic review has been registered on PROSPERO (CRD42020155895).
FINDINGS
Of 6162 potentially eligible publications, six were eligible and we obtained data for all of the six publications (n=3660 participants). The pooled proportion of inpatients eligible for an Xpert was 90% (95% CI 89-91; n=3658). Among screening tests to guide diagnostic testing, W4SS and C-reactive protein (≥5 mg/L) had highest sensitivities (≥96%) but low specificities (≤12%); cough (≥2 weeks), haemoglobin concentration (<8 g/dL), body-mass index (<18·5 kg/m
INTERPRETATION
The W4SS and other potential screening tests to guide Xpert testing have suboptimal accuracy in HIV-positive inpatients. On the basis of these findings, WHO now strongly recommends molecular rapid diagnostic testing in all medical HIV-positive inpatients in settings where tuberculosis prevalence is higher than 10%.
FUNDING
World Health Organization.
Identifiants
pubmed: 35338834
pii: S2352-3018(22)00002-9
doi: 10.1016/S2352-3018(22)00002-9
pmc: PMC8964502
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e233-e241Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203135/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214321/Z/18/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products, or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Lancet. 2018 Jul 28;392(10144):292-301
pubmed: 30032978
J Acquir Immune Defic Syndr. 2014 May 1;66(1):33-40
pubmed: 24346639
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
J Int AIDS Soc. 2016 Jan 12;19(1):20714
pubmed: 26765347
PLoS Med. 2011 Jan 18;8(1):e1000391
pubmed: 21267059
Lancet HIV. 2015 Oct;2(10):e438-44
pubmed: 26423651
BMC Med. 2017 Aug 4;15(1):145
pubmed: 28774293
PLoS Med. 2015 Jul 21;12(7):e1001855
pubmed: 26196287
Cochrane Database Syst Rev. 2019 Sep 30;9:CD012777
pubmed: 31565799
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
Cochrane Database Syst Rev. 2021 Feb 22;2:CD009593
pubmed: 33616229
Clin Microbiol Infect. 2019 Feb;25(2):169-177
pubmed: 30076971
Clin Infect Dis. 2018 Apr 17;66(9):1419-1426
pubmed: 29126226
Stat Med. 2001 Oct 15;20(19):2865-84
pubmed: 11568945
Sci Rep. 2016 Jan 20;6:19391
pubmed: 26786396
Clin Infect Dis. 2010 May 15;50(10):1377-86
pubmed: 20388036
PLoS One. 2017 Jan 26;12(1):e0170976
pubmed: 28125693
PLoS Med. 2020 May 1;17(5):e1003113
pubmed: 32357197
Int J Health Policy Manag. 2014 Aug 13;3(3):123-8
pubmed: 25197676
Diagn Microbiol Infect Dis. 2020 Jan;96(1):114892
pubmed: 31727376
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
AIDS. 2015 Sep 24;29(15):1987-2002
pubmed: 26266773
BMC Med. 2017 Mar 21;15(1):67
pubmed: 28320384
BMC Infect Dis. 2018 Aug 14;18(1):399
pubmed: 30107791
Lancet HIV. 2018 Sep;5(9):e515-e523
pubmed: 30139576
BMC Med. 2015 Aug 14;13:192
pubmed: 26275908
Stat Methods Med Res. 2017 Aug;26(4):1896-1911
pubmed: 26116616
Open Forum Infect Dis. 2020 Dec 23;8(2):ofaa639
pubmed: 33575422
Lancet Infect Dis. 2022 Apr;22(4):507-518
pubmed: 34800394
BMC Infect Dis. 2015 Oct 01;15:407
pubmed: 26427365
Epidemiology. 2020 Sep;31(5):713-717
pubmed: 32657954
J Clin Epidemiol. 2006 Dec;59(12):1331-2; author reply 1332-3
pubmed: 17098577
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
Lancet Infect Dis. 2020 Jun;20(6):742-752
pubmed: 32178764
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120